Today: 14 May 2026
Browse Category

NASDAQ:NDRA 13 October 2025

Biotech Meets Crypto: ENDRA Life Sciences (NDRA) Stock Skyrockets 33% — Analyst Target $50

Biotech Meets Crypto: ENDRA Life Sciences (NDRA) Stock Skyrockets 33% — Analyst Target $50

ENDRA Life Sciences shares surged 33% to $8.63 midday Oct. 13, 2025, after announcing a $4.9 million crypto-asset treasury placement managed by Arca. The company’s main TAEUS imaging product targets liver fat measurement, with a 250-patient FDA trial underway. Q2 net loss narrowed to $1.2 million, with cash at $1.8 million as of June 30. Analyst coverage is limited; the 12-month price target stands at $50.
13 October 2025
·

Stock Market Today

  • Quantinuum Prepares for IPO Amid Ongoing Research-Intensive Development
    May 14, 2026, 11:11 AM EDT. Quantum computing firm Quantinuum is pursuing an initial public offering (IPO) as it continues its research-driven development. The company focuses heavily on advancing quantum technology, a market with growing investor interest due to its potential to revolutionize computing. Donovan Jones, an IPO research specialist with 15 years' experience, highlights that Quantinuum's IPO filing reflects the company's strategic move to raise capital for further innovation. The IPO process involves multiple stages including the filing, listing, quiet period, and lockup expiration. Quantinuum's approach underlines the trend of advanced technology companies seeking public funding to scale research efforts in emerging sectors.

Latest articles

IREN Stock Rises as $2.6 Billion Debt Deal Tests Its Nvidia AI Ambitions

IREN Stock Rises as $2.6 Billion Debt Deal Tests Its Nvidia AI Ambitions

14 May 2026
IREN Limited shares climbed 4.7% to $57.75 in New York after the company priced $2.6 billion in 1.00% convertible senior notes due 2033, up from a $2 billion plan. The offering, expected to close May 14, follows a $3.4 billion AI cloud services contract and a strategic partnership with Nvidia. IREN reported a $247.8 million net loss for the March quarter. JPMorgan raised its price target to $46 but maintained an Underweight rating.
Redwire Stock Jumps Again as $498 Million Backlog Puts Defense Growth Back in Play

Redwire Stock Jumps Again as $498 Million Backlog Puts Defense Growth Back in Play

14 May 2026
Redwire shares jumped nearly 14% to $13.04 Thursday after reporting first-quarter revenue up 57.9% to $97 million and reaffirming its 2026 sales outlook. The company ended March with a $498.1 million backlog but posted a $76.5 million net loss. Redwire also launched a $350 million at-the-market share program, raising dilution concerns.
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

14 May 2026
Biogen closed its $5.3 billion acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and ending its Nasdaq listing. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains Syfovre and Empaveli, which generated $689 million in 2025 revenue. Biogen funded the deal with $2 billion in unsecured term loans.
Intel Stock Falls Again as AMD and Arm Put Its Comeback Under Pressure

Intel Stock Falls Again as AMD and Arm Put Its Comeback Under Pressure

14 May 2026
Intel shares fell 3.9% to $115.55 Thursday after UBS data showed its server CPU market share dropped to 54.9% in Q1, down from 64.4% a year earlier, while AMD and Arm gained ground. The decline comes despite Intel reporting Q1 revenue of $13.6 billion and announcing a multi-year partnership with McLaren Racing.
Go toTop